Gay and bisexual men who inject drugs: Findings from an HIV bio-behavioural surveillance study in Aotearoa/New Zealand

Authors:

PETER J. SAXTON1,2, DAVID NEWCOMBE2, GEOFF NOLLER3, KATHRYN LEAFE3

1Gay Men’s Sexual Health research group, University of Auckland, Auckland, New Zealand, 2Centre for Addiction Research (CFAR), University of Auckland, Auckland, New Zealand, 3New Zealand Needle Exchange Programme, Christchurch, New Zealand.

Presenter’s email: d.newcombe@auckland.ac.nz

Introduction: New Zealand has sustained an excellent record preventing HIV among people who inject drugs (PWID). Although HIV prevalence in PWID accessing needle exchange programmes is low (0.2%), it is higher (7.7%) among gay and bisexual men who report injecting drug use (GBM/IDU), reflecting dual transmission risks. There is scarce New Zealand evidence to inform contemporary policy and programmes; we therefore analysed data on HIV prevalence and sexual behaviour from a previous surveillance study.

Method: Data were collected among GBM in 2011 from gay community settings and internet dating sites. Participation was voluntary, anonymous and self-completed. Items included sexual behaviour, HIV and STI testing, and injecting drug use history (<6 months, >6 months ago, never). A sub-study in Auckland community sites invited participants to provide an oral fluid specimen that was tested for HIV antibodies.

Key Findings: 3,163 GBM participated of whom 5.4% had injected ever and 1.2% <6 months (“recent” injectors). Recent injectors were more likely to report: being younger, being diagnosed HIV positive (22.4% vs 4%), >20 recent male partners (35.1% vs 8.2%), recent sex with a woman (35.1% vs 15.2%), any recent condomless sex with a casual male partner (58.3% vs 29.7%), and an STI diagnosis <12 months (24.3% vs 8%) compared to other participants (all p<0.001). HIV positive recent injectors typically reported riskier behaviours than HIV negative recent injectors, and the latter riskier behaviours than other participants. Of the Auckland sub-sample providing specimens (80%), actual HIV prevalence was 20%, 21.3% and 5.3% among recent injectors, former-injectors and never-injectors respectively.

Conclusion: GBM/IDU are a sentinel group with high HIV and STI burden.

Implications for Practice or Policy: Bisexual behaviour potentially means GBM/IDU play a bridging role in HIV, HCV and other STI outbreaks. Access to NEP and PrEP is critical.

Implications for Translational Research: Updated research is needed to understand the attitudes of GBM/IDU to contemporary harm reduction practices and treatments.

Disclosure of Interest Statement:

No pharmaceutical grants were received in the development of this study.